|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GBM cell lines capable of forming caveolae expressed more uPA and matrix metalloproteinase-2 (MMP-2) and/or -9 (MMP-9) and were more invasive than GBM cells devoid of caveola-forming proteins.
|
30949900 |
2019 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression of these MMPs was markedly increased in most GBMs with excellent correlation between mRNA and protein levels; activated forms of MMP-2 and MMP-9 were present in 8/18 and 7/18 of GBMs.
|
12918061 |
2003 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This prospective, case control study was aimed to find out an association of MMP-2 gene polymorphism with susceptibility to develop glioblastoma in Indian population.
|
21483125 |
2011 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We find that MMP-2 activity in human U251 GBM xenografts increases (*P=0.03) and collagen IV content decreases (*P=0.01) during vascular endothelial growth factor (VEGF-A) antibody neutralization.
|
22673390 |
2013 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones.
|
16598420 |
2006 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We analysed the transcript expression of CLEC5A in glioblastoma by accessing The Cancer Genome Atlas (TCGA). qRT-PCR was performed to detect the RNA expression of genes in cells and tissues, and Western blot was used to measure the protein levels (Cyclin D1, Bcl-2, BAX, PCNA, MMP2, MMP9, Akt and Akt phosphorylation) in tissues and cells.
|
30834619 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tivozanib diminished GBM cell invasion through impairing the proteolytic cascade of cathepsin B/urokinase-type plasminogen activator (uPA)/matrix metalloproteinase-2 (MMP-2).
|
28287096 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This cannabinoid-induced inhibition of MMP-2 expression in gliomas (a) was MMP-2-selective, as levels of other MMP family members were unaffected; (b) was mimicked by JWH-133, a CB(2) cannabinoid receptor-selective agonist that is devoid of psychoactive side effects; (c) was abrogated by fumonisin B1, a selective inhibitor of ceramide biosynthesis; and (d) was also evident in two patients with recurrent glioblastoma multiforme.
|
18339876 |
2008 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest that VEGFa may regulate MMP2 in glioblastoma, while MMP2 did not appear to affect VEGFa levels.
|
25213694 |
2014 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DTCM-g also reduces the invasion capacity of all GBM cell lines without alterations in MMP2 and uPa expression.
|
29683097 |
2018 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the expression of MMP-2, its inhibitor TIMP-2 and the tumour invasiveness-related protein SPARC were effectively inhibited by TRAIL in glioblastoma cell lines.
|
16622457 |
2006 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consistent with this idea, 39% less extracellular MMP2 was measured from knockdown cells identifying one mechanism by which calpain 2 mediates glioblastoma cell invasion.
|
20730561 |
2010 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A significant decline of MMP-9 and MMP-2 secretion in cultured U87MG was detected after incubation with EBB (42.9% and 73.0%, respectively) and EBB + TMZ (38.4% and 68.5%, respectively).
|
25256634 |
2014 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor growth rate and final tumor weight were significantly increased in the animals with the glioblastoma derived from transfected U87-H4645 cells, compared to untransfected and vector control (p<0.01). mRNA expression of β-catenin, CD44, ICAM-1, and MMP-2 in the glioblastoma derived from the transfected U87-H4645 tumors was significantly increased compared with tumors derived from untransfected and vector-control U87 cells (p<0.01).
|
29848673 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemically, MT1-MMP and MT2-MMP are localized to the neoplastic astrocytes in glioblastoma samples (17/17 cases and 12/17 cases, respectively), which are also positive for MMP-2.
|
10027400 |
1999 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Further research into the underlying mechanism demonstrated that the effects of miR-125b on the invasion of glioblastoma CD133-positive cells were associated with the alteration of the expression of MMPs (MMP-2 and MMP-9) and corresponding inhibitors (RECK and TIMP3).
|
22711523 |
2012 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Similarly, U87MG cells engineered to overexpress TIMP-2 at the same levels as U87-C1 cells also demonstrated increased MMP-2 activation, indicating that an increase in physiological levels of TIMP-2 can promote MMP-2 activation and invasion in glioblastoma cells.
|
14631378 |
2004 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Activation of PI3K/AKT signaling prevented the suppressive effects of RWDD3 downregulation on glioblastoma cell proliferation and migration, concurrent with increased protein levels of MMP2 and MMP9.
|
29977365 |
2018 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Characterization of matrix metalloproteinase-2 and -9, ADAM-10 and N-cadherin expression in human glioblastoma multiforme.
|
25948484 |
2015 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that siRNA delivery significantly decreased levels of MMP-2 in the glioblastoma cell lines U-87 and U-251.
|
18438431 |
2008 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
By virtue of its restricted expression in GBM and its role in invasion, Necl-5 may be an attractive target for limiting MMP-2 production in glioblastoma, and therefore limiting dispersal.
|
20680398 |
2011 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells.
|
11853893 |
2002 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, tissue microarray analysis of 68 GBM tissue specimens showed a significant correlation between the overexpression of IGFBP2 and elevated MMP-2 expression.
|
12907597 |
2003 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Measurements of MMP-2 intensity increased with tumor grade, and MMP-2 expression was found to be significantly higher in glioblastomas compared to normal brain tissue (p<0.001), diffuse astrocytomas (p<0.001) and anaplastic astrocytomas (p<0.05).
|
28234925 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In medulloblastomas, the expression of mt1-MMP, mt2-MMP, and gelatinase A were also increased, but to a lesser extent than that observed in glioblastomas.
|
9708803 |
1998 |